A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single and Multiple Dose Safety, Tolerability, and Pharmacokinetics Study of PF-04805712 in Healthy Volunteers

NCT00991016

Healthy Volunteers

TERMINATED PHASE1

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

NCT02066909

Healthy

COMPLETED PHASE1

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

NCT02184429

Healthy

COMPLETED PHASE1

A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers

NCT01265732

Healthy

WITHDRAWN PHASE1

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

NCT01169714

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suspension

PF-02413873 suspension

Group Type EXPERIMENTAL

150 mg Suspension

Intervention Type DRUG

Single oral dose of 150 mg of PF-02413873 suspension

30 mg Suspension

Intervention Type DRUG

Single oral dose of 30 mg of PF-02413873 suspension

400 mg Suspension

Intervention Type DRUG

Single oral dose of 400 mg of PF-02413873 suspension

5 mg Suspension

Intervention Type DRUG

Single oral dose of 5 mg of PF-02413873 suspension

750 mg Suspension

Intervention Type DRUG

Single oral dose of 750 mg of PF-02413873 suspension

Tablet

PF-02413873 Phase 2 Tablets

Group Type EXPERIMENTAL

150 mg Tablet

Intervention Type DRUG

Single oral dose of 150 mg of PF-02413873 tablets

30 mg Tablet

Intervention Type DRUG

Single oral dose of 30 mg of PF-02413873 tablets

400 mg Tablet

Intervention Type DRUG

Single oral dose of 400 mg of PF-02413873 tablets

5 mg Tablet

Intervention Type DRUG

Single oral dose of 5 mg of PF-02413873 tablets

750 mg Tablet

Intervention Type DRUG

Single oral dose of 750 mg of PF-02413873 tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

150 mg Suspension

Single oral dose of 150 mg of PF-02413873 suspension

Intervention Type DRUG

30 mg Suspension

Single oral dose of 30 mg of PF-02413873 suspension

Intervention Type DRUG

400 mg Suspension

Single oral dose of 400 mg of PF-02413873 suspension

Intervention Type DRUG

5 mg Suspension

Single oral dose of 5 mg of PF-02413873 suspension

Intervention Type DRUG

750 mg Suspension

Single oral dose of 750 mg of PF-02413873 suspension

Intervention Type DRUG

150 mg Tablet

Single oral dose of 150 mg of PF-02413873 tablets

Intervention Type DRUG

30 mg Tablet

Single oral dose of 30 mg of PF-02413873 tablets

Intervention Type DRUG

400 mg Tablet

Single oral dose of 400 mg of PF-02413873 tablets

Intervention Type DRUG

5 mg Tablet

Single oral dose of 5 mg of PF-02413873 tablets

Intervention Type DRUG

750 mg Tablet

Single oral dose of 750 mg of PF-02413873 tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male and female volunteers.
* Female volunteers have to be of non-childbearing potential

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* Any condition possibly affecting drug absorption (eg, gastrectomy).
* A positive urine drug screen.

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes